RESUMEN
For forensic and clinical toxicologic purposes, cannabis consumption is screened using easy-to-handle immunoassays. The sensitivity and specificity of these immunoassays have not yet been established in samples from volunteers receiving oral synthetic tetrahydrocannabinol or cannabis extracts using liquid chromatography-mass spectrometry/mass spectrometry as the reference method. Urine samples were collected in an open, randomized, single-center, three-period crossover study including 18 healthy male volunteers given either 20 mg synthetic tetrahydrocannabinol (Marinol) as a control substance or five different types of Cannabis sativa extracts.
Asunto(s)
Cannabinoides/orina , Administración Oral , Adulto , Calibración , Cannabinoides/administración & dosificación , Cannabis/química , Cromatografía Líquida de Alta Presión , Reacciones Cruzadas , Dronabinol/administración & dosificación , Dronabinol/orina , Humanos , Hidrólisis , Inmunoensayo , Masculino , Extractos Vegetales/farmacocinética , Psicotrópicos/administración & dosificación , Psicotrópicos/orina , Control de Calidad , Curva ROC , Estándares de Referencia , Soluciones , Espectrometría de Masas en Tándem , Adulto JovenRESUMEN
A novel high-performance liquid chromatographic separation method with tandem-mass spectrometry detection was developed for the simultaneous determination of Delta(9)-tetrahydrocannabinol (THC) and its major metabolites 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC) and 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) as well as the components cannabidiol (CBD) and cannabinol (CBN) in human EDTA-plasma and urine. Run time was 25 min. Lower limit of quantification was 0.2 ng/ml. The coefficients of variation of all inter- and intra-assay determinations were between 1.3 and 15.5%. The method was successfully applied to the determination of cannabinoids in human plasma and human urine after administration of Delta(9)-tetrahydrocannabinol or Cannabis sativa extracts.
